Hemolytic Uremic Syndrome is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hemolytic Uremic Syndrome have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hemolytic Uremic Syndrome compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hemolytic Uremic Syndrome overview

Hemolytic uremic syndrome (HUS) is a rare but serious condition that affects the blood vessels and kidneys. It is caused by the damage and inflammation of small blood vessels, which leads to the formation of blood clots that block the flow of blood and oxygen to the organs. HUS can result in anemia, low platelet count, and kidney failure. The most common cause of HUS is infection with certain strains of Escherichia coli (E. coli) bacteria that produce a toxin called Shiga toxin. These bacteria are usually found in contaminated food or water, especially undercooked meat, unpasteurized milk, or raw fruits and vegetables. Other causes of HUS include other infections, certain medications, pregnancy, cancer, or autoimmune diseases. Most people recover from HUS with proper treatment, but some may have long-term kidney problems or other complications.

For a complete picture of PTSR and LoA scores for drugs in Hemolytic Uremic Syndrome, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.